Continuation-in-part of application No. 09/580,535, filed on May 26, 2000, and a
continuation-in-part of application No. 09/444,172, filed on Nov. 19, 1999, which is a …

QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural
products NC (N)= NCCCC (N) C (= O) N1CCCC1C (= O) N1C (C (= O) NCC (= O) NC (CC …

2002-09-23 Assigned to CORVAS INTERNATIONAL, INC. reassignment CORVAS
INTERNATIONAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR …

6,087,473 A 7/2000 Conklin et a1 ' 2004/0209243 A1 10/2004 Nixon et a1. 6,090,916 A
7/2000 Vlasuk et a1 ' 2005/0004021 A1 l/2005 Sprecher et a1. 6,103,499 A 55/2000 …

Plasma kallikrein is a serine protease component of the contact system and a potential drug
target for different inflammatory, cardiovascular, infectious (sepsis) and oncology diseases …

Related US Application Data Primary Examiner—Chih-Min Kam (63) Continuation of
application No. 1 1/796,272, filed on (74) Attorney, Agent, or Firm—Lando & Anastasi, LLP …

Related US Application Data Continuation of application No. 1 1/796,272, filed on Apr. 27,
2007, now abandoned, which is a continuation of application No. 1 1/322,960, filed on Dec …

Methods are described for preventing or reducing ischemia and/or systemic inflammatory
response in a patient Such as perioperative blood loss and/or systemic inflammatory …

US8034775B2 - Kallikrein-inhibitor therapies - Google Patents US8034775B2 - Kallikrein-inhibitor
therapies - Google Patents Kallikrein-inhibitor therapies Download PDF Info Publication …

Methods, kits and compositions are described that include a non-naturally occurring
kallikrein inhibitor and an anti-thrombolytic agent, eg, an anti-fibrinolytic agent, for …